Proprietary Therapeutic molecule Systemic Delivery Technology
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
24
NCT05740280
iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects
Phase: Phase 1
Role: Lead Sponsor
Start: Jan 19, 2023
Completion: Apr 20, 2023
Loading map...